• Spirocyclic POM Analogues as MmpL3 Inhibitors

  2026-09-20

  This 2024 Bioorganic Chemistry study develops spirocyclic phenyl oxazole methyl analogues as a new chemical series against Mycobacterium tuberculosis. The lead compound 5c combined submicromolar activity with activity against drug-resistant clinical isolates, favorable early pharmacology, low THP-1 cytotoxicity, and genetic evidence implicating the essential transporter MmpL3.

• Ceftazidime B3539 for Reliable Assays

  2026-09-19

  Learn how Ceftazidime SKU B3539 can support controlled antimicrobial and infection-model workflows without obscuring mammalian cell viability readouts. This scenario-based guide covers solvent compatibility, stock handling, susceptibility testing, resistance interpretation, and practical product selection.

• Cardiogreen: Reliable Cell Assay Workflows

  2026-09-18

  Learn how Cardiogreen (Indocyanine Green), SKU B8315, can support controlled viability, proliferation, cytotoxicity, and photodynamic therapy workflows. This scenario-based guide covers optical interference, treatment controls, solution handling, mechanistic interpretation, and practical vendor selection.

• BAP1, SLC7A11, and Disulfidptosis in Cancer

  2026-09-18

  The reference study identifies BAP1 as a suppressor of disulfidptosis, linking its transcriptional control of SLC7A11 to cystine flux and cellular NADPH availability. Its findings show how the same BAP1–SLC7A11 axis can oppose disulfidptosis while promoting ferroptosis, emphasizing the importance of metabolic context when interpreting tumor suppressor function.

• Mouse Neutrophil Cell Isolation Kit: Assay Logic

  2026-09-17

  The Mouse Neutrophil Cell Isolation Kit supports rapid, high-purity enrichment while minimizing direct labeling of target cells. This article explains how tissue origin, selection chemistry, and assay design affect interpretation in neutrophil-targeted immunotherapy research.

• Meropenem trihydrate in Resistance Workflows

  2026-09-17

  Use Meropenem trihydrate as a controlled antibacterial perturbation for MIC testing, resistance phenotyping, and metabolomics-informed assay design. This workflow connects rapid LC-MS/MS signatures with practical experiments in gram-negative bacterial infections and translational infection models.

• BML-277 for Reproducible Chk2 Assays

  2026-09-16

  Learn how BML-277, SKU B1236, can support controlled Chk2 inhibition in biochemical, viability, and radiation-response workflows. This scenario-based guide connects product specifications with practical assay design, interpretation, storage, and supplier-selection decisions.

• Dual-Mode mRNA Readouts for Translation and Delivery

  2026-09-16

  Translational mRNA research increasingly requires two answers from one experiment: where the RNA goes and whether it produces functional protein. This thought-leadership article examines how Cap1 capping, 5-moUTP modification, Cy5 labeling, and Firefly Luciferase reporting can support that decision framework, while using the vorinostat lipoplex study to clarify what delivery and expression data can—and cannot—prove.

• Meropenem: From PBP Action to Resistance Mapping

  2026-09-15

  Meropenem is a β-lactam antibiotic carbapenem whose value in research extends beyond susceptibility testing. This article connects PBP pharmacology with plasmid transmission, helping researchers design more interpretable assays for carbapenem-resistant bacterial infections and Gram-negative infection models.

• Aurora A in Retinoblastoma: Evidence for Targeted Therapy

  2026-09-15

  A 2024 American Journal of Pathology study identifies AURKA overexpression as a recurrent feature of human retinoblastoma and links it to histopathologic indicators of high-risk disease. By combining patient-tissue analysis with genetic and pharmacologic perturbation in cellular, patient-derived, and xenograft models, the work supports AURKA as a candidate vulnerability while defining its relationship with MYCN.

• tFUS Suppresses Stroke Neuroinflammation via SHP2

  2026-09-14

  This study identifies the Nespas/miR-383-3p/SHP2 axis as a mechanistic link between low-intensity transcranial focused ultrasound stimulation and suppression of NLRP3-mediated neuroinflammation after ischemic stroke. Rat and BV2 microglial experiments connect tFUS treatment with improved neurological outcomes, reduced infarction, and lower inflammasome activation, while also defining experimental entry points for studying SHP2-dependent microglial responses.

• Meropenem: Mechanism to Resistance Strategy

  2026-09-14

  A translational perspective on Meropenem that connects PBP-targeted bactericidal activity with carbapenemase mobility, resistance-aware assay design, and strategic use in Gram-negative infection models.

• JNK-IN-7: Causal Mapping of Infection Apoptosis

  2026-09-13

  JNK-IN-7 is a selective JNK inhibitor for dissecting c-Jun signaling, pathogen-induced apoptosis, and innate immune responses. This article presents a phase-resolved assay strategy that separates MAPK pathway activity from downstream cell-death execution.

• Ertapenem Sodium Salt in Resistance Workflows

  2026-09-12

  Build a practical Ertapenem sodium salt workflow that links broth microdilution with carbapenemase detection, plasmid localization, and transfer analysis. The approach converts a broad-spectrum phenotype into evidence for antibiotic resistance research while clearly separating assay observations from clinical interpretation.

• Protease and Phosphatase Inhibitor Cocktail Workflow

  2026-09-11

  Protect protein abundance and phosphorylation states from the moment cells or tissues are disrupted. This EDTA-free, 100X formulation is especially useful for metal-sensitive signaling assays, phosphoprotein immunoblotting, organoid studies, and comparative proteomics.

7967 records 1/532 page Next 12345 下5页 Last page